Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
Abstract Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Wiley
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/5e76b6d89eee413f87ad7fef882ea071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|